erlotinib hydrochloride has been researched along with Cancer of Duodenum in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burke, CA; Buttar, N; Cruz-Correa, M; Das, R; Della'Zanna, G; Foster, N; Kanth, P; Limburg, PJ; Mankaney, G; McMurray, RP; Richmond, E; Rodriguez, LM; Samadder, NJ; Sossenheimer, M; Stoffel, E; Szabo, E; Thirumurthi, S; Turgeon, DK; Umar, A; Vilar, E; Westover, M; Zahrieh, D | 1 |
| Akiyama, N; Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inui, N; Iwaizumi, M; Karayama, M; Kono, M; Kusama, Y; Nakamura, Y; Suda, T; Suzuki, Y | 1 |
1 trial(s) available for erlotinib hydrochloride and Cancer of Duodenum
| Article | Year |
|---|---|
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Duodenal Neoplasms; Duodenum; Endoscopy, Gastrointestinal; Erlotinib Hydrochloride; Female; Humans | 2023 |
1 other study(ies) available for erlotinib hydrochloride and Cancer of Duodenum
| Article | Year |
|---|---|
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Duodenal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Pyrimidines; Quinazolines; Treatment Outcome | 2017 |